Trial · NCT03043820
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
NCT03043820, Phase 3, Completed, Iris Sommer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder. Trials, record NCT03043820. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03043820
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
- NCT number
- NCT03043820
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 110 participants, actual
- Lead sponsor
- Iris Sommer
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Interventions
- Raloxifene, Placebo
- First posted
- 2017-02-06
- Last updated
- 2021-10-08
- Other registries' IDs
- eudract:2015-004483-11
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in symptom severity as measured with the Positive and Negative Symptom Scale (PANSS) | Baseline, at 6 weeks of treatment, at 12 weeks of treatment (end of treatment) and 6 months after end of treatment (follow-up) | Effect of the study therapies on symptom severity. |
| Primary | Change in cognitive functioning as measured with the Brief Assessment of Cognition in Schizophrenia | Baseline, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up) | Effect of the study therapies on cognitive functioning |
| Secondary | Personal and social performance measured with the Personal and Social Performance scale (PSP) | Baseline, at 6 weeks, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up) | Effect of the study therapy on personal and social performance. |
| Secondary | Thought disorder severity as measured with the Thought And Language Disorder scale (TALD) | Baseline, at 6 weeks, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up) | Effect of the study therapy on severity of thought disorder. |
| Secondary | Participant's Quality of Life as measured with the EQ-5D-5L | Baseline, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up) | Effect of the study therapy on quality of life. |
| Secondary | Comorbid depression as measured with Beck's Depression Inventory (BDI). | Baseline, at 6 weeks, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up) | Effect of the study therapy on comorbid depression |
| Secondary | Use of health-recourses as measured with the iMTA-MCQ | Baseline, at 12 weeks (end of treatment) and 6 months follow-up | Effect of the study therapy on use of recourses. |
| Secondary | Use of non-health recourses as measured with the iMTA-PCQ | Baseline, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up) | Effect of the study therapy on use of recourses. |
| Secondary | Language production assessment by analyzing speech samples | Baseline and at 12 weeks of treatment (end of treatment) | Effect of the study therapy on free speech. |
| Secondary | Symptom severity as measured with the Brief Negative Symptom Scale (BNSS) | Baseline, at 6 weeks, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up) | Effect of the study therapies on symptom severity. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25914107 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03043820
GET https://conductscience.org/api/trials/v1/NCT03043820/registered